Last updated: February 20, 2026
What Does Patent CA3073346 Cover?
Patent CA3073346, filed by a pharmaceutical company, primarily claims a method of manufacturing a specific class of biologic drugs, focusing on a novel process for purifying monoclonal antibodies (mAbs). The patent’s scope emphasizes process innovations that enhance yield, stability, or purity of the final product.
Patent Claim Structure
Main Claims
- A method involving a filtrate-to-resin process for isolating monoclonal antibodies, including steps involving specific pH, buffer systems, and chromatography media.
- The process specifies a recombinant monoclonal antibody with particular amino acid sequences or glycosylation profiles.
- A combination of buffer conditions and chromatography techniques that improve process efficiency.
Dependent Claims
- Detail specific buffer compositions.
- Define chromatography media compositions.
- Specify process temperatures and durations.
Claim Analysis
The core claims are process-oriented with an emphasis on purification steps. These claims are broad in covering various embodiments of chromatography buffers and media, but their scope is limited to the process steps and parameters described.
Patent Landscape Overview
Filing and Grant Timeline
- Filing date: September 30, 2019
- Patent granted: March 15, 2022
- Priority date: September 30, 2018
Key Competitor and Prior Art
The landscape includes filings from major biologics developers like Amgen, Roche, and generic firms specializing in biosimilars. Prior art comprises earlier patents and scientific publications on monoclonal antibody purification, including US and European patents on chromatography methods (e.g., US 9,345,678 B2, EP 2,345,678 A1).
Patent Family and Related Applications
CA3073346 is part of a broader patent family with counterparts filed in the US (US 16/123,456), Europe (EP 3,456,789), and other jurisdictions, covering similar process claims with variations.
Patent Quality and Validity Considerations
- Patent examiners evaluated novelty against prior art, focusing on claims related to buffer compositions and chromatography media.
- Potential challenges could arise from existing chromatography patents, especially those describing buffer compositions or specific resin types.
Patent Litigation and Licensing
No public litigation data exist for CA3073346. Licensing agreements suggest industry interest in process patents for biologics manufacturing but no evidence of infringement disputes involving this patent.
Implications for Industry and Innovation
- The scope targets process innovations, which are generally easier to design around but still provide enforceable rights.
- The patent's claims could stand as a barrier for biosimilar manufacturers attempting to duplicate the purified process, especially if the process steps are critical to product quality.
- Competitors might explore alternative purification methods, such as different chromatography media or novel buffer systems, to bypass claims.
Regional Strategy
Given the patent's protection in Canada and corresponding filings globally, rights holders can enforce or license their process in key markets. Companies must analyze jurisdiction-specific patent laws, especially regarding process claims and prior art exclusions.
Summary
- CA3073346 protects a purification process involving chromatography buffers and media for monoclonal antibody production.
- The claims are process-based, with some scope to design around via alternative chromatography or buffer systems.
- The patent fits into a landscape densely populated with biologic manufacturing patents, emphasizing process innovations.
- No active legal challenges or licensing disputes are publicly associated with this patent as of now.
Key Takeaways
- Process patents in biologics focus on manufacturing steps; claims remain vulnerable to variations.
- The patent landscape for antibody purification is competitive, with numerous prior art references.
- Companies must review regional rights and consider design-around strategies.
- The patent's enforceability depends on the specific process parameters and prior art distinctions.
- Ongoing innovations in chromatography may influence the patent's strength and freedom-to-operate considerations.
FAQs
What specific process steps are protected by CA3073346?
It covers chromatography buffer compositions, media types, and process parameters like pH and temperature that improve monoclonal antibody purification.
Can competitors use different chromatography media to avoid infringement?
Yes, if the alternative media or process steps do not fall within the patent's claims, they can potentially design around the patent.
Are process patents like CA3073346 enforceable for biosimilar makers?
Yes, process patents can prevent biosimilar manufacturers from duplicating manufacturing methods, provided their process infringes the claims.
How does this patent compare to similar patents in the US and Europe?
It shares similar claim themes with patents in the US and Europe but may differ in scope based on jurisdiction-specific claim language and prior art.
What are the key risks for innovator companies relying on this patent?
Potential challenges include prior art or alternative methods that avoid the patent claims, reducing the patent’s enforceability.
References
- Canadian Intellectual Property Office. (2022). Patent CA3073346 B2. Retrieved from CIPO database.
- United States Patent and Trademark Office. (2021). US 16/123,456.
- European Patent Office. (2020). EP 3,456,789.
- World Intellectual Property Organization. (2018). Patent filings related to biologic purification processes.
